In univariable survival analysis, Grubmüller et al. [39] showed that after administering two cycles of PSMA-RPT, total tumor volume (TTV) as a first-order RF on PSMA PET had the potential to assess response in mCRPC patients. The gene discussed is FOLH1; the disease is neoplasm.